好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Overview of Psychiatric Disorders and Treatment in Patients with Lennox-Gastaut Syndrome in a LATAM Specialized Center
Epilepsy/Clinical Neurophysiology (EEG)
P7 - Poster Session 7 (5:00 PM-6:00 PM)
9-015

Describe the prevalence of psychiatric comorbidities and use of psychotropic medications in patients with Lennox-Gastaut Syndrome (LGS).

LGS is a pharmacoresistant childhood-onset epileptic encephalopathy  that is accompanied by behavioral comorbidities, hyperactivity, and psychosis. Up to 90% of patients develop neuropsychiatric disorders, which tend to worsen over time, even if seizures improve.

An observational, descriptive, cross-sectional study was conducted on patients diagnosed with LGS at our Epilepsy Clinic, SPSS® 23 was used for data analysis. Quantitative variables were summarized with mean and standard deviation, while qualitative variables were expressed as frequencies and percentages.

Forty patients were included, 27  (67.5%) men, with a mean age of 35.8 ± 9.3 years. The average number of antiseizure drugs (ASD) was 3.4 ± 3. Among all, 28 patients (70%) underwent surgery, primarily anterior callosotomy (21, 52.5%). Generalized seizures were common in 29 patients (72.5%), and epilepsy was mostly combined (30, 75%). All 40 patients (100%) had intellectual developmental impairments. Additionally, 21 patients (52.5%) presented psychiatric comorbidities. Among them, 10 (25%) experienced aggression and behavioral disturbances, 4 (10%) had psychosis, 3 (7.5%) had depression, 1 (2.5%) reported anxiety, and 1 (2.5%) faced sleep disturbances. Psychotropic medications were administered to 24 patients (60%), with 5 (12.5%) receiving risperidone as monotherapy, followed by sertraline in 3 (7.5%), fluoxetine in 2 (5%), and clonazepam, haloperidol, and quetiapine in 1 (2.5%) each. Additionally, polytherapy was utilized, including risperidone with SSRIs in 3 (7.5%) and fluoxetine with olanzapine in 2 (5%).

The most common comorbidity was intellectual developmental impairments. Moreover, half of the patients had psychiatric comorbidities, with behavioral disturbances and psychosis being the most common, as documented in literature. This highlights the importance of early diagnosis and treatment, as these conditions worsen prognosis.

Authors/Disclosures
Fernando Vasquez Lopez, MD
PRESENTER
Dr. Vasquez Lopez has nothing to disclose.
Jimena Colado, MD Dr. Colado has nothing to disclose.
Jimena Gonzalez Salido, MD Miss Gonzalez Salido has nothing to disclose.
Irving Fuentes Mr. Fuentes has nothing to disclose.
Betsy C. Vazquez, MD Dr. Vazquez has nothing to disclose.
Eithel A. Valenzuela Mendivil Eithel A. Valenzuela Mendivil has nothing to disclose.
Mijail A. Rivas, Sr., MD (Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Juarez) Dr. Rivas has nothing to disclose.
Gerardo Méndez Suárez, Sr., MD Dr. Méndez Suárez has nothing to disclose.
Salvador Martinez-Medina, MD Dr. Martinez-Medina has nothing to disclose.
Mario Sebastian-Diaz, MD, PhD Dr. Sebastian-Diaz has nothing to disclose.
Angel A. Ruiz-Chow, Sr., MD Dr. Ruiz-Chow has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for J&J. Dr. Ruiz-Chow has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for J&J.
Daniel Crail-Melendez, MD Prof. Crail-Melendez has nothing to disclose.